Appendix A: Online Search Strategies

Total Page:16

File Type:pdf, Size:1020Kb

Appendix A: Online Search Strategies APPENDIX A: ONLINE SEARCH STRATEGIES Kidney and HCV module 1. exp kidney glomerulus/ 2. exp kidney disease/ 3. exp kidney function tests/ 4. exp renal replacement therapy/ 5. exp kidney transplantation/ 6. exp kidney, artificial/ 9. renal.af. or renal.tw. 10. nephro$.af. or nephro$.tw. 11. kidney.af. or kidney.tw. 12. ur?emia.af. or ur?emia.tw. 13. h?emodialysis.af. or h?emodialysis.tw. 13a. dialysis.tw 14. (hemofiltr$ or haemofiltr$).af. or (hemofiltr$ or haemofiltr$).tw. 15. or/1-14 16. exp Hepatitis C/ 17. hepatitis c.mp. 18. hep c.tw. 19. HCV.af. 20. or/16-19 21. 15 and 20 22. limit to humans Diagnostic tests 1. (enzyme immunoassay$ or immune, essay$ or EIA or NAT or nucleic acid amplification test$ or test$, nucleic acid or amplification technique$, nucleic acid or tech$, nucleic acid amplification)af. 2. limit 1 to yr-“2008-current” 3. (biops$, liver or liver biops$ or APRI or ((aspartate aminotransferase or ast) and platelet and (ratio or index)) or fibrotest or fibrosure or fibroscan or transient elastography or elastography, transient or elastography).af 4. 2 or 3 5. 4 not (“addresses”[pt] or “autobiography”[pt] or “bibliography”[pt] or “biography”[pt] or “case reports”[pt] or “comment”[pt] or “congresses”[pt] or “dictionary”[pt] or “directory”[pt] or “editorial”[pt] or “festschrift”[pt] or “government publications”[pt] or “historical article”[pt] or “interview”[pt] or “lectures”[pt] or “legal cases”[pt] or “legislation”[pt] or “letter”[pt] or “news”[pt] or “newspaper article”[pt] or “patient education handout”[pt] or “periodical index”[pt] or "comment on" or review[tw] OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] or cow[tw] or cows[tw] or chicken*[tw] or horse[tw] or horses[tw] or mice[tw] or mouse[tw] or bovine[tw] or sheep or ovine or murine) 6. 5 and “kidney and HCV module” Predictor studies 1. (incidence or follow-up studies or prognosis).sh or exp models, statistical or (prognos$ or predict$ or course or diagnosed).tw or cohort.mp 2. 1 not (“addresses”[pt] or “autobiography”[pt] or “bibliography”[pt] or “biography”[pt] or “case reports”[pt] or “comment”[pt] or “congresses”[pt] or “dictionary”[pt] or “directory”[pt] or “editorial”[pt] or “festschrift”[pt] or “government publications”[pt] or “historical article”[pt] or “interview”[pt] or “lectures”[pt] or “legal cases”[pt] or “legislation”[pt] or “letter”[pt] or “news”[pt] or “newspaper article”[pt] or “patient education handout”[pt] or “periodical index”[pt] or "comment on" or review[tw] OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] or cow[tw] or cows[tw] or chicken*[tw] or horse[tw] or horses[tw] or mice[tw] or mouse[tw] or bovine[tw] or sheep or ovine or murine) 3. 2 and “kidney and HCV module” DAA or non-DAA treatment 1. (telaprevir or boceprevir or danoprevir or RG$7227 or faldaprevir or BI201335 or vaniprevir or MK$7009 or sovaprevir or ACH$1625 or simeprevir or TMC435 or asunaprevir or BMS$650032 or paritaprevir or ABT$450 or grazoprevir or MK$5172 or vedroprevir or GS$9451 or daclatasvir or BMS$790052 or ombitasvir or ABT$267 or ledipasvir or GS$5885 or samatasvir or IDX$719 or elbasvir or MK$8742 or GS$5816 or ACH$3102 or sofosbuvir or GS$7977 or mericitabine or RG$7128 or valopicitabine or MK$3682 or setrobuvir or ANA598 or tegobuvir or GS$9190 or filibuvir or PF$868554 or dasabuvir or ABT$333 or deleobuvir or BI$207127 or beclabuvir or BMS$791325 or ABT$072 or GS$9669 or VX$222).af 2. ribavirin.af. or (interferon or IFN).af. or (pegylated interferon or pegylated IFN).af. 3. limit 2 to yr-“2011-current” 4. 1 or 3 5. 4 and (((pre-post[tw] or "pre test*"[tw] or pretest*[tw] or posttest*[tw] or "post test*"[tw] or (pre[tw] and post[tw])))) OR ((pre-workshop[tw] or post-workshop[tw] or (before[tw] and workshop[tw]) or (after[tw] and workshop[tw])))) OR (trial[tw] or ((study[tw] and aim*[tw]) or "our study"[tw]))) OR ((before[tw] and (after[tw] or during[tw])))) OR (("quasi-experiment*" or quasiexperiment* or "quasi random*" or quasirandom* or "quasi control*" or quasicontrol* or ((quasi or experimental) and (method or study or trial or design*))))) OR (("time series" and interrupt*))) OR ((time points[tw] and (over[tw] or multiple[tw] or three[tw] or four[tw] or five[tw] or six[tw] or seven[tw] or eight[tw] or nine[tw] or ten[tw] or eleven[tw] or twelve[tw] or month*[tw] or hour*[tw] or day[tw] or days[tw] or "more than"[tw])))) OR pilot[tw]) OR "Pilot Projects"[Mesh]) OR ((clinical trial[pt] or controlled clinical trial[pt] or multicenter study[pt]))) OR ((multicentre[tw] or multicenter[tw] or multi-centre[tw] or multi-center[tw]))) OR (random*[tw] or controlled[tw])) OR ((control[tw] and (area[tw] or cohort*[tw] or compare*[tw] or condition[tw] or design[tw] or group[tw] or groups[tw] or grouping[tw] or intervention*[tw] or participant*[tw] or study[tw])) NOT (((("comment on" or review[tw] or review [pt])) OR (("Animals"[Mesh] NOT "Humans"[Mesh]))) OR ((rat[tw] or rats[tw] or cow[tw] or cows[tw] or chicken*[tw] or horse[tw] or horses[tw] or mice[tw] or mouse[tw] or bovine[tw] or animal*[tw]))))) or ("Epidemiologic Studies"[Mesh] OR "Case-Control Studies"[Mesh] OR "Cohort Studies"[Mesh] or "Cross-Sectional Studies"[Mesh] OR “Case control” OR cohort OR (Follow up AND (study or studies)) OR (observational and (study or studies)) OR Longitudinal OR Retrospective OR cross section* OR cross-section* OR "Prospective Studies"[Mesh] OR "Longitudinal Studies"[Mesh] "Follow-Up Studies"[Mesh] OR (follow-up or followup)) or (systematic[sb] OR meta-analysis[pt] OR meta- analysis as topic[mh] OR meta-analysis[mh] OR meta analy* OR metanaly* OR metaanaly* OR met analy* OR (systematic AND (review* OR overview*)) OR "Review Literature as Topic"[Mesh] OR cochrane[tiab] OR embase[tiab] OR (psychlit[tiab] or psyclit[tiab]) OR (psychinfo[tiab] or psycinfo[tiab])OR (cinahl[tiab] or cinhal[tiab]) OR science citation index[tiab] OR bids[tiab] OR cancerlit[tiab] OR reference list*[tiab] OR bibliograph*[tiab] OR hand-search*[tiab] OR relevant journals[tiab] OR manual search*[tiab] OR selection criteria[tiab] OR data extraction[tiab]) or ((pharmacokinetic or pharmacodynamic).tw or exp Clinical Trial, Phase II/ or exp Clinical Trial, Phase III/) 6. 5 and “kidney and HCV module” Isolation 1. (isolat$ or transmi$ or quarantine or sequestra$ or segregat$ or separat$).af 2. 1 not (addresses or bibliography or biography or comment or dictionary or directory or editorial or festschrift or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or "review" or review, academic or review, tutorial) 3. 2 and “kidney and HCV module” Transplant topics 1. exp kidney transplantation/ 2. (kidney or renal).af 3. exp transplantation/ 4. exp allograft/ 5. 1 or (2 and (3 or 4)) 6. exp Hepatitis C/ 7. hepatitis c.mp. 8. hep c.tw. 9. HCV.af. 10. or/6-9 11. 5 and 10 12. limit 11 to humans 13. limit 12 to (addresses or bibliography or biography or comment or dictionary or directory or editorial or festschrift or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or "review" or review, academic or review, tutorial) 14. 12 not 13 Glomerulonephritis 1. glomerulonephritis.mp. or exp Glomerulonephritis/ 2. glomerulopathy.tw. 3. immunotactoid glomerulopathy.tw 4. exp Nephrotic Syndrome/ 5. exp Glomerulonephritis, Membranous/ 6. glomerulonephrit$.tw. 7. exp Glomerulonephritis, Membranoproliferative/ 8. membranous nephropathy.tw. 9. (IGA nephropathy or immunoglobulin A nephropathy).mp. or IGAN.tw. 10. exp Glomerulonephritis, IgA/ 11. rapidly progressive glomerulonephr$.tw. 12. RPGN.tw. 13. (focal sclerosing glomerulopathy or FSGS).tw. 14. Sclerosing Glomerulonephrit$.tw. or sclerosing glomerulonephritis/ 15. glomerulosclerosis.tw. 16. Mesangiocapillary Glomerulonephrit$.tw. 17. (Hypocomplementemia and Glomerulonephritis).tw. 18. Berger's disease.mp. or Bergers.tw. 19. Focal segmental glomerulosclerosis.mp. or focal segmental glomerulo$.tw. 20. Goodpasture syndrome.mp. or Goodpasture.tw. 21. Nephritis.mp. or Nephritis.tw. 22. exp Purpura, Schoenlein-Henoch/ 23. (exp Antibodies, Antineutrophil Cytoplasmic/ and vasculitis/et) or (ANCA adj1 vasculitis).tw. 24. exp Glomerulosclerosis, Focal Segmental/ 25. exp Nephrosis, Lipoid/ 26. Minimal change nephropathy.mp. 27. minimal change disease.mp. 28. churg-strauss syndrome/ or wegener granulomatosis/ 29. exp Lupus Nephritis/ or Lupus nephritis.mp. 30. renal vasculitis.tw. 31. fibrillary glomerulonephritis.tw 32. amyloidosis.tw 33. or/1-32 34. exp Hepatitis C/ 35. hepatitis c.mp. 36. hep c.tw. 37. HCV.af. 38. or/34-37 39. 33 and 38 40. limit 39 to yr=”2008-current” 41. limit 40 to humans 42. limit 41 to (addresses or bibliography or biography or comment or dictionary or directory or editorial or festschrift or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or "review" or review, academic or review, tutorial) 43. 41 not 42 .
Recommended publications
  • Sofosbuvir/Ledipasvir for HIV •
    Hepatitis C: Drugs and Combinations Melissa Osborn MD Associate Professor MetroHealth Medical Center Case Western Reserve University Cleveland, OH Faculty and Planning Committee Disclosures Please consult your program book. Off-Label Disclosure The following off-label/investigational uses will be discussed in this presentation: • Sofosbuvir/ledipasvir for HIV •. Investigational agents for hepatitis C will be mentioned – Asunaprevir – Daclatasvir – Beclabuvir – Grazoprevir – Elbasvir – GS-5816 Learning Objectives Upon completion of this presentation, learners should be better able to: • apply clinical trial data on new hepatitis C therapies to their patient population. • select which new hepatitis C therapies are appropriate to use with common antiretrovirals. Evolution of interferon-based therapy in HCV-monoinfected genotype 1 patients Sustained Virologic Response 100% 90% 80% 80% 75% 67% 60% 42% 46% 40% 28% 20% 7% 0% Std interferon-alfa IFN + RBV Peg-alfa-2b+RBV Peg-alfa-2a +RBV P/R/Telaprevir P/R/Boceprevir P/R/Simeprevir P/R/Sofosbuvir McHutchison, NEJM 1998; 339: 1485-92 Jacobson, NEJM 2011; 364:2405-16 Fried, NEJM 2002; 347: 975-82 Poordad, NEJM 2011; 364: 1195-206 Manns, Lancet 2001; 358:958-65 Jacobson, AASLD 2013 #1122 Lawitz, NEJM 2013 Evolution of HCV Therapy: Genotype 1 Patients Naïve to Therapy: HIV-HCV coinfection Sustained Virologic Response 80% 75% 74% 67% 61% 60% 46% 42% 40% 28% 29% 20% 17% 7% 7% 0% Std interferon-alfa IFN + RBV Peg-alfa-2b+RBV Peg-alfa-2a +RBV P/R/Telaprevir P/R/Boceprevir Torriani, NEJM, 2004 351:438-50
    [Show full text]
  • Hepatitis C Treatment
    Hepatitis C Treatment The goal of treatment for hepatitis C virus (HCV) is to cure the virus, which can be done with a combination of drugs. The specific meds used and the duration of treatment depend on a number of factors, including HCV genotype (genetic structure of the virus), viral load, past treatment experience, degree of liver damage, ability to tolerate the prescribed treatment, and whether the person is waiting for a liver transplant or is a transplant recipient. In some cases, HCV treatment may be limited by your health insurance plan or drug formulary. Here’s information about each type, or class, of approved HCV treatment along with drugs in the late stages of development: Multi-Class Combination Drugs Brand Name Generic Name Status Pharmaceutical Company Epclusa* sofosbuvir + velpatasvir Approved Gilead Sciences Harvoni* ledipasvir + sofosbuvir Approved Gilead Sciences Mavyret glecaprevir + pibrentasvir Approved AbbVie Vosevi sofosbuvir/velpatasvir/ Approved Gilead Sciences voxilaprevir Zepatier elbasvir + grazoprevir Approved Merck n/a daclatasvir + asunaprevir + Phase III Bristol-Myers Squibb beclabuvir *generic available What are they? Multi-class combination drugs are a combination of drugs formulated into a single pill or package of pills. For instance, the drug Harvoni combines two drugs, ledipasvir and sofosbuvir. Ledipasvir is an NS5A inhibitor and is only sold as part of Harvoni; sofosbuvir may be prescribed separately under the brand name of Sovaldi. Pegylated Interferon Alfa Brand Name Generic Name Status Pharmaceutical Company Pegasys peginterferon alfa-2a Approved Genentech What are they? Interferon is a protein made by the immune system, named because it interferes with viral reproduction. In addition, interferon signals the immune system to recognize and respond to microorganisms, including viral and bacterial infections.
    [Show full text]
  • Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 197 Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors Targeting Different Genotypes and Drug-Resistant Variants ANNA KARIN BELFRAGE ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6192 ISBN 978-91-554-9166-6 UPPSALA urn:nbn:se:uu:diva-243317 2015 Dissertation presented at Uppsala University to be publicly examined in B41 BMC, Husargatan 3, Uppsala, Friday, 27 March 2015 at 09:15 for the degree of Doctor of Philosophy (Faculty of Pharmacy). The examination will be conducted in Swedish. Faculty examiner: Ulf Ellervik (Lunds tekniska högskola). Abstract Belfrage, A. K. 2015. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors. Targeting Different Genotypes and Drug-Resistant Variants. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 197. 108 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9166-6. Since the first approved hepatitis C virus (HCV) NS3 protease inhibitors in 2011, numerous direct acting antivirals (DAAs) have reached late stages of clinical trials. Today, several combination therapies, based on different DAAs, with or without the need of pegylated interferon-α injection, are available for chronic HCV infections. The chemical foundation of the approved and late-stage HCV NS3 protease inhibitors is markedly similar. This could partly explain the cross-resistance that have emerged under the pressure of NS3 protease inhibitors. The first-generation NS3 protease inhibitors were developed to efficiently inhibit genotype 1 of the virus and were less potent against other genotypes. The main focus in this thesis was to design and synthesize a new class of 2(1H)-pyrazinone based HCV NS3 protease inhibitors, structurally dissimilar to the inhibitors evaluated in clinical trials or approved, potentially with a unique resistance profile and with a broad genotypic coverage.
    [Show full text]
  • Bristol-Myers Setback Another Blow to Hep C Field
    August 24, 2012 Bristol-Myers setback another blow to hep C field Joanne Fagg The once-crowded field of candidates jostling to be part of the first all-oral hepatitis C antiviral cocktail got decidedly emptier today with the news that Bristol-Myers Squibb had cancelled development of its $2bn asset BMS-986094. The safety worries that had triggered a clinical hold on the drug turned out too deep to accept – a death in the original heart failure patient, plus nine other hospitalised subjects resulting from heart and kidney toxicity. Excitement around the space has already dissipated with Gilead Sciences’ seemingly uninterrupted march towards the all-oral holy grail and signs that the untreated population might be smaller than was originally believed. Failure of a closely watched candidate – and indeed one validated by a big pharma deal – will do nothing to reinvigorate the interest of investors whose interest may be turning elsewhere. Hefty price tag The news is not necessarily a setback for the nucleoside NS5B polymerase inhibitor class or for Bristol-Myers, which still has a decent pipeline in spite of some failures (see tables). However, it is another knock to sentiment for developers in the hep C space – at least, the ones that are not called Gilead (Signs are growing that the hep C ship is sailing, August 1, 2012). Hepatitis C nucleoside NS5B polymerase inhibitor pipeline Status Product Company Selected trial IDs NCT01497366 NCT01542788 Phase III GS-7977 Gilead Sciences NCT01604850 NCT01641640 NCT00869661 Phase II RG7128 Gilead Sciences/Roche NCT01057667 NCT01278134 IDX184 Idenix Pharmaceuticals Partial clinical hold Phase I RO5303253 Roche NCT01181024 NCT01371162 RO5428029 Roche NCT01345942 ALS-2200 Vertex Pharmaceuticals NCT01590407 ALS-2158 Vertex Pharmaceuticals NCT01554085 As if further confirmation were needed, California-based Gilead is now decisively in the lead to get a much- heralded all-oral hepatitis C combination to the market and address those patients thought to be awaiting a therapy free of interferon and its side effects.
    [Show full text]
  • Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for Biomedical Research, Inc
    VIROLOGICA SINICA, August 2010, 25 (4):246-266 DOI 10.1007/s12250-010-3140-2 © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2010 Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for BioMedical Research, Inc. Cambridge, Massachusetts 02139, USA) Abstract: Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
    [Show full text]
  • Reviews in Basic and Clinical Gastroenterology
    GASTROENTEROLOGY 2010;138:447–462 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY REVIEWS IN BASIC AND CLINICAL John P. Lynch and David C. Metz, Section Editors GASTROENTEROLOGY Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection CHRISTOPH SARRAZIN and STEFAN ZEUZEM J. W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany Chronic hepatitis C virus (HCV) infection is one of agents that are also named specific, targeted antiviral the major causes of cirrhosis, hepatocellular carci- therapies (STAT-C) for HCV infection are in phase 1–3 noma, and liver failure that leads to transplantation. trials. We review resistance to DAA agents, focusing on The current standard treatment, a combination of compounds in development such as reagents that target pegylated interferon alfa and ribavirin, eradicates the the HCV nonstructural (NS)3 protease, the NS5A pro- virus in only about 50% of patients. Directly acting tein, and the RNA-dependent RNA polymerase NS5B. We antiviral (DAA) agents, which inhibit HCV replica- also discuss indirect inhibitors or compounds that in- tion, are in phase 1, 2, and 3 trials; these include hibit HCV replication by not yet completely resolved reagents that target the nonstructural (NS)3 protease, mechanisms, such as cyclophilin inhibitors, nitazox- the NS5A protein, the RNA-dependent RNA-polymer- anide, and silibinin (Table 1, Figure 1). ase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell Parameters That Affect Resistance proteins. Because of the high genetic heterogeneity of Heterogeneity of HCV HCV and its rapid replication, monotherapy with HCV has a high rate of turnover; its half-life was DAA agents poses a high risk for selection of resistant estimated to be only 2–5 hours, with the production and variants.
    [Show full text]
  • Update Sulle Terapie Farmacologiche Nell’Infezione Da Hcv
    UPDATE SULLE TERAPIE FARMACOLOGICHE NELL’INFEZIONE DA HCV Giorgio Barbarini Già responsabile Unità Semplice “Diagnosi e terapia delle Malattie Infettive correlate alla Tossicodipendenza” DIPARTIMENTO MALATTIE INFETTIVE E TROPICALI April 21, 1989 Hepatitis C is the silent global epidemic of the 21st Century 2015 • ~72 million people with viraemic HCV • ~8.1 million people with HCV-related liver cirrhosis • ~261,000 people with HCV-related HCC • ~7000 HCV-related liver transplants • ~370,000 HCV liver-related deaths Viraemic prevalence 0.0–<0.6% 0.6–<0.8% 0.8–<1.3% 1.3–<2.9% 2.9–<6.7% Blach S, et al. Lancet Gastroenterol Hepatol 2017;2:161–76; The Polaris Observatory. Hepatitis C. Available at: http://polarisobservatory.org/polaris/hepC.htm (accessed April 2017) Seroprevalence of Hepatitis C: 150 to 200 Million Worldwide Eastern Europe 10 M Western Pacific 60 M United States Western Europe 5M 5 M Southeast Asia Highest Prevalence: 30-35 M Egypt-4M Americas (45% adults >40y) 12-15 M Africa 30-40M Australia .2 M 1. World Health Organization. Wkly Epidemiol Rec. 2000;75:17-28. 2. Edlin B et al. AASLD; November 11-15; 2005 San Francisco, California. Oral Presentation #44. 3. Fontanet A. Annual Report of Emerging Diseases for Year 2005. Accessed 03/13/06 at http://www.pasteur.fr/recherche/RAR/RAR2005/Epimal-en.html Distribution of HCV in the EU Viremic prevalence 0.64% Total viremic pool 3,238,000 New yearly infections 57,900 (plus ~30,000 from immigration) Lancet Gastroenterol Hepatol 2017;2:325-336 The European Union HCV Collaborators: Lancet Gastroenterol Hepatol 2017; 2: 325-36.
    [Show full text]
  • WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T (51) International Patent Classification: (74) Agent: PINO, Mark, J.; Connolly Bove Lodge & Hutz C07D 417/04 (2006.01) A61K 31/542 (2006.01) LLP, 1875 Eye Street, Nw, Suite 1100, Washington, DC C07D 513/04 (2006.01) A61P 31/14 (2006.01) 20006 (US). A61K 31/5415 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 12/032297 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 5 April 2012 (05.04.2012) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/472,286 6 April 201 1 (06.04.201 1) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US) : ANADYS (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC.
    [Show full text]
  • Pessimism Infects Achillion As FDA Sustains Clinical Hold
    September 30, 2013 Pessimism infects Achillion as FDA sustains clinical hold Jonathan Gardner Another disappointment for the hepatitis C project sovaprevir may have Achillion Pharmaceuticals feeling like it is starting all over again. At a time when the Connecticut-based group could be riding the bio-runup heading into the AASLD liver meeting in November, executives disclosed that the FDA would not lift the clinical hold imposed after liver enzyme elevations were detected in a drug interaction study (Another hep C safety worry buffets Achillion’s lead, July 2, 2013). Shares crashed 55% to a four-year low of $3.28 in early trading today on the news, released after Friday’s market close. Acknowledging the setback, executives signalled that they were prepared to move on, with phase II testing of alternative treatment regimens imminent; while that may be an attempt to reassure, it adds months if not years to investors’ assumptions about when Achillion will start generating a royalty stream. Just like starting over With first approval decisions for Gilead Sciences’ expected $11bn drug sofosbuvir due by December and combinations from Bristol-Myers Squibb and AbbVie making strides forward, the all-oral market looks to be well served by 2017. This year is the likely earliest point that any of Achillion’s assets could begin generating sales; in 2017, Gilead’s sofosbuvir-centred franchise is expected to yield $8.2bn in sales, according to EvaluatePharma's consensus. However, Achillion executives sought to portray the company's hep C activities as broader than sovaprevir, a protease inhibitor, highlighting the NS5A inhibitor ACH-3102, a second protease inhibitor, ACH-2684, which will report combination tests with ‘3102 next year, and a uridine-analog nucleotide, ACH-3422, which could be in the clinic next year.
    [Show full text]
  • Meeting Report: 26Th International Conference on Antiviral Research Q
    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
    [Show full text]
  • HCV Eradication with Direct Acting Antivirals (Daas)?
    HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d’Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. [email protected] HCV eradication with direct acting antivirals (DAAs)? HCV replication HCV genome and DAAs targets NS3 inhibitors NS5A inhibitors NS5B inhibitors Take home messages HCV viral cycle Asselah et al. Liver Int. 2015;35 S1:56-64. Direct acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir Direct Acting Antivirals: 2015 Asselah et al. Liver Int. 2015;35 S1:56-64. Genetic barrier for HCV direct acting antivirals High Nucleos(t)ide 1 mutation= high cost to Analog Inhibitors fitness, 2-3 additional mutations to increase fitness 2 st generation Protease Inhibitors n Non Nucleos(t)ide Analog Inhibitors : NS5 A Inhibitors 1 st generation Protease Inhibitors 1 mutation= low cost to fitness Low Halfon et al. J Hepatol 2011. Vol 55(1):192-206. HCV protease inhibitors (PI) Inhibit NS3/NS4A serine protease responsible for the processing of the polyprotein 1st generation 1st generation, 2nd wave 2nd generation Resistance low low high barrier Genotype activity 1: 1 a< 1b All except 3 all Drug drug Important Less Less interaction Drugs Boceprevir Simeprevir (Janssen) MK-5172 Telaprevir Faldaprevir (BI) ACH-2684 Paritaprevir (ABT-450)/r (AbbVie) Vedroprevir (Gilead) Vaniprevir (Merck) Sovaprevir (Achillion) Asunaprevir (BMS) NS3/NS4A structure Repositioning of helicase domain Self cleavage Lipid Bilayer Inactive Insertion of the Active carboxy-terminal tail Bartenschlager et al.
    [Show full text]
  • Web Annex 3.1. Adult Hepatitis C Virus Treatment Systematic Review
    Web Annex 3.1. Adult hepatitis C virus treatment systematic review Michael Zoratti, Hamilton, Canada In: Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection July 2018 i WHO/CDS/HIV/18.36 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Zoratti M. Web Annex 3.1. Adult hepatitis C virus treatment systematic review. In: Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.
    [Show full text]